ArticleCrohn's & colitis 3602020

Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab.

Michael Chiorean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.